Deoxymethoxetamine (DMXE) is an arylcyclohexylamine known for producing dissociative effects, such as euphoria, dissociation, derealization, depersonalization, and sensory modulation, often with a clear-headed and stimulating quality compared to other dissociatives. It acts primarily as an NMDA receptor antagonist, disrupting normal neural signaling, and rearranging brain energy distribution, which is believed to be responsible for its reality-altering effects. Due to its recent emergence, limited data exists on its potential therapeutic benefit. The IP-NFT embodies the intellectual property produced through DMXE research conducted by Zeus Tipado as a part of the PsyDAO Early Career Fellowship.